Unicycive Therapeutics Inc.'s (UNCY) Oxylanthanum Carbonate, proposed for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis, is back at the FDA altar again, awaiting a decision on June 29, 2026.Hyperphosphatemia, characterized by elevated phosphate levels in the blood, is a common and serious condition in nearly all patients with End-Stage Renal Disease (ESRD). Although there are several FDA-cleared medications for Hyperphosphatemia, 75% of U.S. dialysis patients fail to achieve the target phosphorus levels recommended by published medical guidelines.This is the company’s second attempt to secure approval for Oxylanthanum Carbonate. The regulatory agency declined to approve the drug in June 2025, citing deficiencies in the compliance status of the third-party manufacturing vendor.According to the company, if approved, Oxylanthanum Carbonate could improve patient adherence compared to current treatments because it requires fewer and smaller pills per dose, and the pills can be swallowed instead of chewed, making them more convenient.UNCY closed Tuesday’s (June 2, 2026) trading at $7.23, down 4.87%.